Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(φ)-LMC GROUP)

Leukemia

Volumn 20, Issue 6, 2006, Pages 1061-1066

  Nicolini, F E ^a   Corm, S ^b,c   Le Q H ^a   Sorel, N ^d   Hayette, S ^e   Bories, D ^f   Leguay, T ^g   Roy, L ^d   Giraudier, S ^f   Tulliez, M ^f   Facon, T ^b   Mahon, F X ^g   Cayuela, J M ^h   Rousselot, P ⁱ   Michallet, M ^a   Preudhomme, C ^b,c   Guilhot, F ^d   Roche Lestienne, C ^b,c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d University of Poitiers   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ CHU   (France)

Author keywords

BCR ABL mutations; CML; Imatinib mesylate; P loop; T315I

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL PROTOCOL; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 33744461022     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404236     Document Type: Article

References (26)

1. O'Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
2. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
3. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
4. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75-85.
5. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004; 11: 35-43.
6. von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sanger J, Seipel P et al. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2005; 105: 1652-1659.
7. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI 571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014-1018.
8. Kreuzer KA, Le Coutre P, Landt O, Na IK, Schwarz M, Schultheis K et al. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol 2003; 82: 284-289.
9. Willis S, Lange T, Demehri S, Otto S, Crossman N, Niederwieser D et al. High sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128-2137.
10. Chu S, Xu H, Shah N, Snyder DS, Forman SJ, Sawyers CL et al. Detection of BCR-ABL kinase mutations in CD34+ cells form chronic myelogenous leukaemia patients in complete cytogenetic remission on imatinib mesylate treatment. Leukemia 2005; 5: 2093-2098.
11. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-283.
12. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Pocrio A et al. ABL mutations in late chronic phase chronic myeloid leukaemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 2005; 18: 4100-4109.
13. Hochhaus A, Hughes T. Clinical resistance to imatinib: Mechanisms and implications. Hematol Oncol Clin N Am 2004; 18: 641-656, ix.
14. Hochhaus A, Kreil S, Corbin AS, LaRosée P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI 571) therapy. Leukemia 2002; 16: 2190-2196.
15. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukaemia or Ph-positive acute lymphoblastic leukaemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472-3475.
16. Crossman LC, O'Hare T, Lange T, Willis SG, Stoffregen EP, Corbin AS et al. A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity of imatinib. Leukemia 2005; 19: 1859-1862.
17. Nicolini FE, Chabane K, Cayuela J-M, Rousselot P, Thomas X, Hayette S. The K247R substitution in the ABL tyrosine kinase domain is not a mutation leading to imatinib resistance, but a rare polymorphism. Haematologica/Hematol J 2006; 91: 137-138.
18. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101: 473-475.
19. Corbin AS, La Rosée P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611-4614.
20. Branford S, Rudzki R, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of Bcr-Abl mutations in patients with CML treated with imatinib is virtually always accompanied by mutations in the ATP phosphate-binding loop (P-loop) are associated with poor prognosis. Blood 2003; 102: 276-283.
21. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
22. Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Müller C et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5: 55-60.
23. Hayette S, Michallet M, Baille ML, Magaud JP, Nicolini FE. The assessment and the follow-up of the proportion of T3151 mutant Bcr-Abl transcript can guide adequate therapeutic strategy in CML patients. Leukemia Res 2005; 29: 1073-1077.
24. Allen PB, Weidemann LM. An activating mutation in the ATP binding site of the ABL kinase domain. J Biol Chem 1996; 271: 19585-19591.
25. Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O. The two major imatinib resistance mutations E255K and T3151 enhance the activity of BCR/ABL fusion kinase. Biochem Biosphys Res Common 2004; 319: 1272-1275.
26. Roumantsiev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukaemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002; 99: 10700-10705.